Cargando…

Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data

Patients with polycythemia vera (PV) have a high incidence of thrombotic events (TEs), contributing to a greater mortality risk than the general population. The relationship between hematocrit (HCT) levels and TE occurrence among patients with PV from the Veterans Health Administration (VHA) was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parasuraman, Shreekant, Yu, Jingbo, Paranagama, Dilan, Shrestha, Sulena, Wang, Li, Baser, Onur, Scherber, Robyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848033/ https://www.ncbi.nlm.nih.gov/pubmed/31552445 http://dx.doi.org/10.1007/s00277-019-03793-w

Ejemplares similares

Cytoreductive treatment patterns among US veterans with polycythemia vera
por: Parasuraman, Shreekant, et al.
Publicado: (2018)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)

Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
por: Mo, Jan-Rung, et al.
Publicado: (2009)

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Grunwald, Michael R., et al.
Publicado: (2018)

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Mesa, Ruben, et al.
Publicado: (2018)

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2019)

PB2201: ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT
por: Krecak, Ivan, et al.
Publicado: (2023)

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey
por: Yu, Jingbo, et al.
Publicado: (2020)

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2020)

Trends in overall mortality among US veterans with primary myelofibrosis
por: Tashi, Tsewang, et al.
Publicado: (2023)

Polycythemia Vera Presenting With Normal Hemoglobin and Hematocrit: A Rare Variant
por: Erdinc, Burak, et al.
Publicado: (2020)

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study
por: Zwicker, Jeffrey I., et al.
Publicado: (2021)

Real-world treatments and thrombotic events in polycythemia vera patients in the USA
por: Verstovsek, Srdan, et al.
Publicado: (2023)

The Thrombotic Events in Polycythemia Vera Patients May Be Related to Increased Oxidative Stress
por: Durmus, Ahmet, et al.
Publicado: (2014)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY
por: Gerds, A. T., et al.
Publicado: (2022)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
por: Yokus, Osman, et al.
Publicado: (2023)

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
por: Pósfai, Éva, et al.
Publicado: (2016)

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
por: Accurso, Vincenzo, et al.
Publicado: (2020)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
por: Yu, Jingbo, et al.
Publicado: (2018)

The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events
por: Wang, Xuekun, et al.
Publicado: (2022)

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review
por: Parasuraman, Shreekant, et al.
Publicado: (2016)

Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
por: Baldauf, Conny K., et al.
Publicado: (2022)

Retracted: The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events
por: International, BioMed Research
Publicado: (2023)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

The Association Between Gene Polymorphisms and Leukocytosis with Thrombotic Complications in Patients with Essential Thrombocythemia and Polycythemia Vera
por: Mehtap, Özgür, et al.
Publicado: (2012)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
por: Mulas, Olga, et al.
Publicado: (2023)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_92p2l74oajf7345kcipgbllhb6